Clinical and regulatory intelligence for Anemia with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Assets: 2

Relevant assets

Erythropoietin →

Roxadustat →

Relevant companies

Astellas Pharma →

Recent signals(2)

ClinicalJuly 31, 2026

Study on Erythropoietin's Impact on Hepcidin Levels in Healthy Volunteers

This study aims to assess how intravenous erythropoietin affects serum and urinary hepcidin levels.

ClinicalJuly 27, 2026

Roxadustat Study for Anemia in Children with Chronic Kidney Disease Initiated by Astellas Pharma

Astellas Pharma is conducting a study to evaluate the efficacy of roxadustat in treating anemia in children and teenagers with chronic kidney disease, with a duration of up to 52 weeks.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Anemia →

Hematology →

Nephrology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.